Navigation Links
MacuLogix Raises $3.6 Million in Series A Round
Date:3/11/2013

HUMMELSTOWN, Pa., March 11, 2013 /PRNewswire/ -- MacuLogix, Inc., a pioneer in the early detection and tracking of age-related macular degeneration (AMD), today announced it has raised $3.6 million in Series A funding. Investors include Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania, and Ben Franklin Technology Partners of Central and Northern Pennsylvania.

The funds will be used to accelerate manufacturing and commercial sales of the MacuLogix' AdaptDx™. The AdaptDx™ is being developed to be the first practical diagnostic for early detection and tracking of AMD. Based on significant advances in the measurement of dark adaptation, the AdaptDx™ will provide doctors with an easy-to-use, functional diagnostic similar to routine perimetry testing for glaucoma. With this important new tool, doctors will be able to intervene at the earliest possible time to prevent vision loss and improve quality of life.

"MacuLogix represents a favorable investment opportunity as it addresses a large and growing market for AMD which is the leading cause of adult vision loss and blindness in developed countries," said A. Laurence Norton , Managing Director of Berwind Private Equity. "We understand the AdaptDx™ has the potential to fundamentally transform the way eye doctors detect and manage AMD for millions of people worldwide."

"Closing our Series A round is a very significant achievement for the company," said John G. Edwards , CEO of MacuLogix. "We have completed numerous clinical studies involving more than 1,000 patients with additional studies ongoing, all at major research centers such as Harvard University, the National Eye Institute and University of Alabama at Birmingham. This financing allows us to take the next step."

About MacuLogix
MacuLogix is a pioneer in the early detection and tracking of age-related macular degeneration (AMD). MacuLogix' AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, the AdaptDx™ is not currently cleared for sale as a diagnostic. In addition, the AdaptDx™ is being used by a number of pharmaceutical companies in the development of drugs for early AMD. 

For more information, visit www.maculogix.com


'/>"/>
SOURCE MacuLogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
2. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
3. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
4. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
5. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
6. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
7. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
8. AssureRx Health Raises $12.5 Million Series C Financing
9. InnoPharma Inc. Raises $8 Million in Venture Debt
10. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
11. Retia Medical Raises $7 Million to Develop Accurate, Less-Invasive Cardiovascular Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... 11, 2017  Caris Life Sciences ® , a ... promise of precision medicine, today announced that St. Jude ... Oncology Alliance™ (POA) as its 17 th member. ... Jude Crosson Cancer Institute will help develop standards of ... tumor profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):